On September 23 and 24, Axinn partners Aziz Burgy and Stacie Ropka spoke at the ACI Summit on Biosimilars & Innovator Biologics Virtual Conference.
On September 23, Aziz spoke on a panel entitled, "The Economics of Biosimilars: Considerations for Market Access, Sustainable Pricing and Reimbursement Policies." This panel analyzed the California legislation aimed at ending pay-for-delay in pharmaceutical patent infringement settlements. Speakers reviewed the implications of the House passed Lower Drug Costs Now Act.
On September 24, Stacie spoke on a panel entitled, "In-House Town Hall: An Insider’s Guide to What In-House Counsel Expect from Law Firm Counterparts." This panel reviewed the impact of COVID-19 on global biosimilars market trends and analyzed whether manufacturers pursue interchangeability designations for products.
Click here for more information.